New Drug Brings Hope to Kids With Rare Liver Disease

Children suffering from debilitating itching caused by rare liver diseases finally have hope for relief after a clinical trial delivered remarkable results.

Pharmaceutical company Mirum announced their drug Livmarli succeeded in a major Phase III study involving 52 patients, including many with biliary atresia. This devastating condition leaves babies born with scarred, blocked, or missing bile ducts, causing a dangerous buildup of bile acids that triggers relentless itching.

The EXPAND trial met every goal researchers set. Young patients taking Livmarli saw their itch scores improve by nearly a full point compared to those taking a placebo, while bile acid levels in their blood dropped by 69%. For children with biliary atresia who still had their native liver, the improvement was even stronger.

These results matter deeply because no approved treatments currently exist for biliary atresia. Parents have watched helplessly as their children scratch constantly, unable to sleep or play comfortably. The condition affects quality of life so severely that addressing the itch becomes as important as managing the underlying disease.

Mirum plans to file for FDA approval in the first half of 2027. If approved, Livmarli would become the first therapy specifically authorized to treat biliary atresia, opening a new chapter for families facing this diagnosis.

The drug works by blocking a protein that normally recycles bile acids from the gut back into the liver. By interrupting this cycle, Livmarli helps reduce the bile acid buildup causing the intense itching.

The Ripple Effect

Livmarli is already helping patients with two other rare liver conditions, Alagille syndrome and progressive familial intrahepatic cholestasis. Now its reach could extend to children with biliary atresia and other ultra-rare liver diseases, potentially transforming care for thousands of families worldwide.

The safety profile looked excellent too. Researchers observed no new safety concerns during the trial, giving families and doctors confidence in the treatment approach.

Industry analysts project Livmarli sales could reach $876 million by 2032, reflecting the significant unmet need in rare liver disease communities. But beyond the numbers lie real children who might finally get relief from symptoms that have stolen their comfort and childhood.

Medical advances in ultra-rare diseases often take years longer than treatments for common conditions, making every success story particularly meaningful for small patient communities who've waited so long for answers.